Shanghai, China - MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) recently announced that following Alwide^® Plus Balloon Catheter, the second generation of balloon catheter, Its self-developed new generation Transcatheter Aortic Valve Implantation (" TAVI ") product VitaFlow Liberty^® Transcatheter Aortic Valve and Retrivable Delivery System (" VitaFlow Liberty^® ") has received marketing approval from the Russian State Food and Drug Regulatory Agency (RZN)

Shanghai, China — Recently, MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) has received marketing approval for its second-generation balloon catheter , Alwide^® Plus Balloon Catheter (hereinafter referred to as "Alwide^® Plus") from Russian State Food and Drug Administration(RZN).

On September 4, 2023, at 15:00 local time, the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System ("VitaFlow Liberty^®"), self-developed by MicroPort^® CardioFlow, VitaFlow Liberty^® was presented at the Police General Hospital in Thailand. Under the leadership of Prof. Luo Jianfang from Guangdong Provincial People's Hospital, Prof. Anuruck Jeamanukoolkit, an expert from the hospital, together with his team, successfully performed the first implantation of VitaFlow Liberty^® in Thailand. Postoperative imaging showed that the patient's valve was in good shape and position, with no perivalvular leakage or coronary occlusion, and the surgery was a complete success.